Oxeia Biopharmaceuticals, Inc. (OXEA)

Oxeia Biopharmaceuticals was planning to go public, but the IPO was withdrawn on Jun 8, 2022.
Stock Price: Pending
IPO price not available yet

Company Description

Oxeia Biopharmaceuticals is a clinical-stage biotech company developing new, innovative therapies for conditions that are defined by deficits in neurocognition from injury, degeneration and aging.

Our first two indications are for (i) mild traumatic brain injury, known as concussion, and (ii) the cognitive decline, lethargy and “brain-fog” associated with Covid-19 infection, known as Covid Longhauler syndrome (“Long Covid”).

On May 1, 2017, we acquired certain rights to a ghrelin molecule OXE103 that was originally developed by Daiichi Sankyo for non-neurologic indications.

OXE103 has not been approved by the FDA for any non-neurological indications. The license provides access to an open FDA IND containing full preclinical safety data as well as safety data from three human Phase I studies, four multi-dose human Phase II studies, and one Phase III study.

We are currently conducting a Phase 2 study under an FDA approved IND at the University of Kansas Medical Center in two concussion populations.

Oxeia Biopharmaceuticals, Inc.
Country United States
Founded 2014
Industry Health Care
Sector Biotechnology
Employees 2
CEO Dr. Michael Wyand

Contact Details

361 Newbury Street, Suite 500
Boston, MA 02115
United States
Phone (617) 991-9150
Website oxeiabiopharma.com

Stock Details

Ticker Symbol OXEA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001610315
Employer ID 46-5147460
SIC Code 2834

Key Executives

Name Position
Dr. Michael Wyand Chief Executive Officer
Kartik Shah Director and Co-Founder
Julianne Averill Chief Financial Officer
Dr. Vishal Bansal Chief Science Officer and Co-Founder
Alex Smith Director
Ted Raad Director

Latest SEC Filings

Date Type Title
Jun 8, 2022 RW Filing
May 3, 2022 FWP Free Writing Prospectus
Apr 14, 2022 S-1 General form for registration of securities under the Securities Act of 1933
Jan 27, 2022 DRS/A [Amend] [Cover] Draft Registration Statement
Dec 8, 2021 DRS [Cover] Draft Registration Statement
Jun 16, 2014 D Notice of Exempt Offering of Securities